Aggregate deals and financing in cell and gene therapy has dropped by 62% since the peak in 2021. In itself, that's not surprising as during the coronavirus pandemic when lockdowns and travel restrictions freed up so much time that the rate of dealmaking and investing was doubled - maybe fuelled by the extra available energy released by not having to endure the stress of travel or just simply boredom of WFH?. But there is a general loss of appetite in the C> field given that commercial returns have (of course) not lived up to the hype. However, underlying science continues to forge ahead and many suspect there will be a revival in the medium term.
Owner, BioPharma Investment and Management | Lead Biotech Innovation and Strategic Growth
2 个月In the end, it all comes down to the science and the effectiveness of these drugs. If they prove to be game-changers for patients with no other options, price will not be an issue.